FY 2016 PERFORMANCE

F I N A N C I A L R E S U LT S BUSINESS HIGHLIGHTS

SALES WORLDWIDE 1 Abbott Acquires St. Jude Medical

Creates a Premier Medical Device Business

+4.8%
ON OPERATIONAL BASIS*
$
20.9B
SALES WORLDWIDE
STRONG & DIVERSE PORTFOLIO

VASCULAR STRUCTURAL HEART CARDIAC RHYTHM NEUROMODULATION

CARE HEART DISEASE FAILURE MANAGEMENT
BUSINESS SEGMENT SALES

#
12
LEADERSHIP POSITIONS
DIAGNOSTICS 2 NUTRITION 3 OR across large and high-growth cardiovascular
disease device markets
$
4.8B $
6.9B
Raising the Bar on Innovation
+5.5% +1.2% 2016 Key Product Launches

BRANDED GENERIC Alinity systems designed to be more

MEDICAL DEVICES 4 PHARMACEUTICALS 5 efficient and provide quality results for
clinical chemistry, immunoassay, blood
$
5.2B $
3.9B screening and point of care

+4.5% +10.5% ABSORB, THE WORLDS

FIRST BIORESORBABLE
CORONARY STENT
THE FREESTYLE LIBRE PRO,
A REVOLUTIONARY PROFESSIONAL
CONTINUOUS GLUCOSE
MONITORING SYSTEM**

SALES COMPARED TO FY 2015 ON OPERATIONAL BASIS*

1
Reported sales +2.2% 2
Reported sales +3.6% 3
Reported sales (1.1)% 4
Reported sales +3.8% 5
Reported sales +3.7%
*Operational results are non-GAAP as they exclude the impact of foreign exchange. For full financial data and reconciliation of non-GAAP measures, please see our press release dated January 25, 2017,
available at www.abbottinvestor.com.
**Additional FreeStyle Libre Pro information can be found at www.freestylelibrepro.us

FORWARD-LOOKING STATEMENTS
Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbotts operations
are discussed in Item 1A, Risk Factors, to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2015, and St. Jude Medicals Annual Report on Form 10-K for the fiscal year ended
Jan. 2, 2016, respectively, and under the heading Risk Factors in Abbotts Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, and St. Jude Medicals Quarterly Report on Form 10-Q for the fiscal quarter ended
April 2, 2016, which are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

ABBOTT.COM @ABBOTTNEWS; @ABBOTTGLOBAL ABBOTTGLOBAL ABBOTT